Although targeted therapy and endocrine therapy have improved the survival of human epidermal growth factor receptor2 (HER-2)-positive and hormone receptor-positive patients (De Laurentiis et al., 2005; Advani et al., 2015; Grassadonia et al., 2015; Manguso et al., 2015; Moya-Horno & Cortes, 2015), chemotherapy is the only realistic therapeutic approach for BC patients having aggressive tumors with negative ER or PR status. Here, NR4A1 is linked to breast cancer.